HER-2阳性胃癌的研究进展
|
摘要
胃癌是我国最常见的消化道恶性肿瘤之一,随着我国社会经济的发展、人们食物谱的改变,我国的胃癌发病率呈显著上升趋势。人类表皮生长因子受体2(HER-2)是一种原癌基因,在部分胃癌患者中存在高表达,针对HER-2的靶向治疗,可使HER-2阳性的晚期胃癌患者获得显著的生存收益。ToGA研究是胃癌靶向治疗史上的一座里程碑,它首次在大规模样本中证实看联合应用化疗药及曲妥珠单抗可有效延长患者生存期。本文就HER-2阳性胃癌的研究进展作一综述。
Gastric cancer is one of the most common malignant tumors of the digestive tract in China. With the development of China's social economy and the changes in people's food spectrum, the incidence of gastric cancer in China has shown a significant upward trend. Human epidermal growth factor receptor 2(HER-2) is a proto-oncogene that is highly expressed in some patients with gastric cancer. Targeted therapy against HER-2 can significantly improve HER-2 positive patients with advanced gastric cancer. Survival gains. The ToGA study is a milestone in the history of targeted therapy for gastric cancer. It was first demonstrated in large-scale samples that the combination of chemotherapeutic drugs and trastuzumab can effectively prolong patient survival. This article reviews the research progress of HER-2 positive gastric cancer.
Gastric cancer is one of the most common malignant tumors of the digestive tract in China. With the development of China's social economy and the changes in people's food spectrum, the incidence of gastric cancer in China has shown a significant upward trend. Human epidermal growth factor receptor 2(HER-2) is a proto-oncogene that is highly expressed in some patients with gastric cancer. Targeted therapy against HER-2 can significantly improve HER-2 positive patients with advanced gastric cancer. Survival gains. The ToGA study is a milestone in the history of targeted therapy for gastric cancer. It was first demonstrated in large-scale samples that the combination of chemotherapeutic drugs and trastuzumab can effectively prolong patient survival. This article reviews the research progress of HER-2 positive gastric cancer.
引文
[1]An E,Ock CY,Kim TY,et al.Quantitative proteomic analysis of HER2 expression in the selection of gastric cancer patients for trastuzumab treatment[J].Annals of Oncology,2017,28(1):110-115.
[2]Wang H,Wang W,Xu Y,et al.Aberrant intracellular metabolism of T-DM1 confers T-DM1 resistance in HER2-positive gastric cancer cells[J].Cancer Science,2017,108(7):1458-1468.
[3]Shi HZ,Wang YN,Huang XH,et al.Serum HER2 as a predictive biomarker for tissue HER2 status and prognosis in patients with gastric cancer[J].World Journal of Gastroenterology,2017,23(10):1836-1842.
[4]Shin SH,Park SS,Ju EJ,et al.Establishment of a Patient-derived Xenograft for Development of Personalized HER2-targeting Therapy in Gastric Cancer[J].Anticancer Research,2018,38(1):287-293.
[5]Uguen A.About HER2 monitoring using liquid biopsies in patients with gastric cancer[J].Gastric Cancer,2017,20(6):1011-1012.
[6]Liu D,Li X,Chen C,et al.Target-specific delivery of oxaliplatin to HER2-positive gastric cancer cells in vivo using oxaliplatin-au-fe3o4-herceptin nanoparticles[J].Oncology Letters,2018,15(5):8079-8087.
[7]Ji C,Zhang Q,Guan W,et al.Role of intravoxel incoherent motion MR imaging in preoperative assessing HER2 status of gastric cancers[J].Oncotarget,2017,8(30):49293-49302.
[8]Qiu MZ,Shi SM,Chen M,et al.Comparison of HER2 and Lauren Classification between Biopsy and Surgical Resection Samples, Primary and Metastatic Samples of Gastric Cancer[J].Journal of Cancer,2017,8(17):3531-3537.
[9]Zhang X,Yao J,Guo K,et al.The functional mechanism of miR-125b in gastric cancer and its effect on the chemosensitivity of cisplatin[J].Oncotarget,2018,9(2):2105-2119.
[10]Cho JH,Lim JY,Cho JY.Survival analysis based on human epidermal growth factor 2 status in stageⅡ-Ⅲgastric cancer[J].World Journal of Gastroenterology,2017,23(41):7407-7414.
[11]Palle J,Tougeron D,Pozet A.Trastuzumab beyond progression in patients with HER2-positive advanced gastric adenocarcinoma:a multicenter AGEO study[J].Oncotarget,2017,8(60):101383-101393.
[12]王昆宇.1363例胃癌HER-2/neu表达临床流行病学研究[D].吉林大学,2013.
[13]Neves Filho EHC,Pires APB,de Sant'Ana RO,et al.The association among HER2, MET and FOXP3 expression and tumor regression grading in gastric adenocarcinoma[J].Apmis,2018,126(5):389-395.
[14]Lee JS,Kim SH,Im SA,et al.Human Epidermal Growth Factor Receptor 2 Expression in Unresectable Gastric Cancers:Relationship with CT Characteristics[J].Korean Journal of Radiology,2017,18(5):809-820.
[15]Hofmann M,Stoss O,Shi D,et al.Assessment of a HER2scoring system for gastric cancer:results from a validation study[J].Histopathology,2010,52(7):797-805.
[16]《胃癌HER检测指南》编写组.胃癌HER2检测指南[J].中华病理学杂志,2011,40(8):553-557.
[17]《胃癌HER检测指南》专家组.胃癌HER2检测指南(2016版)[J].中华病理学杂志,2016,45(8):528-532.
[18]Kurokawa Y,Sugimoto N,Miwa H,et al.PhaseⅡstudy of trastuzumab in combination with S-1 plus cisplatin in HER2-positive gastric cancer(HERBIS-1)[J].British Journal of Cancer,2014,110(5):1163-1168.
[19]Nishikawa K,Takahashi T,Takaishi H,et al.PhaseⅡstudy of the effectiveness and safety of trastuzumab and paclitaxel for taxane-and trastuzumab-naive patients with HER2-positive, previously treated, advanced, or recurrent gastric cancer(JFMC45-1102)[J].International Journal of Cancer,2016,140(1):188-196.
[20]Yoshioka T,Shien K,Namba K,et al.Antitumor activity of pan-HER inhibitors in HER2-positive gastric cancer[J].Cancer Science,2018,109(4):1166-1176.
[21]Dai GH,Shi Y,Chen L,et al.Trastuzumab combined with docetaxel-based regimens in previously treated metastatic gastric cancer patients with HER2 over-expression[J].Hepatogastroenterology,2012,59(120):2439-2444.
[22]Mitsui Y,Sato Y,Miyamoto H,et al.Trastuzumab in combination with docetaxel/cisplatin/S-1(DCS)for patients with HER2-positive metastatic gastric cancer:feasibility and preliminary efficacy[J].Cancer Chemotherapy&Pharmacology,2015,76(2):375-382.
[23]Al-Batran SE,Hozaeel W,Jager E.Combination of trastuzumab and triple FLOT chemotherapy(5-fluorouracil/leucovorin, oxaliplatin, and docetaxel)in patients with HER2-positive metastatic gastric cancer:report of 3 cases[J].Onkologie,2012,35(9):505-508.
[24]Bang YJ,Van Cutsem E,Feyereislova A,et al.Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer(ToGA):a phase 3, open-label, randomised controlled trial[J].Lancet,2010,376(9742):687-697.
[25]Liang JW,Zhang JJ,Zhang T,et al.Clinicopathological and prognostic significance of HER2 overexpression in gastric cancer:a meta-analysis of the literature[J].Tumor Biology,2014,35(5):4849-4858.
[26]Grabsch H,Sivakumar S,Gray S,et al.HER2 expression in gastric cancer:Rare, heterogeneous and of no prognostic valueconclusions from 924 cases of two independent series[J].Cell Oncol,2010,32(1-2):57-65.
[27]Kang YK,Rha SY,Tassone P,et al.A phaseⅡa dose-finding and safety study of first-line pertuzumab in combination with trastuzumab, capecitabine and cisplatin in patients with HER2-positive advanced gastric cancer[J].British Journal of Cancer,2014,111(4):660-666.
[28]Satoh T,Xu RH,Chung HC,et al.Lapatinib plus paclitaxel versus paclitaxel alone in the second-line treatment of HER2-amplified advanced gastric cancer in Asian populations:TyTAN--a randomized, phaseⅢstudy[J].Journal of Clinical Oncology,2016,32(19):2039-2049.
[2]Wang H,Wang W,Xu Y,et al.Aberrant intracellular metabolism of T-DM1 confers T-DM1 resistance in HER2-positive gastric cancer cells[J].Cancer Science,2017,108(7):1458-1468.
[3]Shi HZ,Wang YN,Huang XH,et al.Serum HER2 as a predictive biomarker for tissue HER2 status and prognosis in patients with gastric cancer[J].World Journal of Gastroenterology,2017,23(10):1836-1842.
[4]Shin SH,Park SS,Ju EJ,et al.Establishment of a Patient-derived Xenograft for Development of Personalized HER2-targeting Therapy in Gastric Cancer[J].Anticancer Research,2018,38(1):287-293.
[5]Uguen A.About HER2 monitoring using liquid biopsies in patients with gastric cancer[J].Gastric Cancer,2017,20(6):1011-1012.
[6]Liu D,Li X,Chen C,et al.Target-specific delivery of oxaliplatin to HER2-positive gastric cancer cells in vivo using oxaliplatin-au-fe3o4-herceptin nanoparticles[J].Oncology Letters,2018,15(5):8079-8087.
[7]Ji C,Zhang Q,Guan W,et al.Role of intravoxel incoherent motion MR imaging in preoperative assessing HER2 status of gastric cancers[J].Oncotarget,2017,8(30):49293-49302.
[8]Qiu MZ,Shi SM,Chen M,et al.Comparison of HER2 and Lauren Classification between Biopsy and Surgical Resection Samples, Primary and Metastatic Samples of Gastric Cancer[J].Journal of Cancer,2017,8(17):3531-3537.
[9]Zhang X,Yao J,Guo K,et al.The functional mechanism of miR-125b in gastric cancer and its effect on the chemosensitivity of cisplatin[J].Oncotarget,2018,9(2):2105-2119.
[10]Cho JH,Lim JY,Cho JY.Survival analysis based on human epidermal growth factor 2 status in stageⅡ-Ⅲgastric cancer[J].World Journal of Gastroenterology,2017,23(41):7407-7414.
[11]Palle J,Tougeron D,Pozet A.Trastuzumab beyond progression in patients with HER2-positive advanced gastric adenocarcinoma:a multicenter AGEO study[J].Oncotarget,2017,8(60):101383-101393.
[12]王昆宇.1363例胃癌HER-2/neu表达临床流行病学研究[D].吉林大学,2013.
[13]Neves Filho EHC,Pires APB,de Sant'Ana RO,et al.The association among HER2, MET and FOXP3 expression and tumor regression grading in gastric adenocarcinoma[J].Apmis,2018,126(5):389-395.
[14]Lee JS,Kim SH,Im SA,et al.Human Epidermal Growth Factor Receptor 2 Expression in Unresectable Gastric Cancers:Relationship with CT Characteristics[J].Korean Journal of Radiology,2017,18(5):809-820.
[15]Hofmann M,Stoss O,Shi D,et al.Assessment of a HER2scoring system for gastric cancer:results from a validation study[J].Histopathology,2010,52(7):797-805.
[16]《胃癌HER检测指南》编写组.胃癌HER2检测指南[J].中华病理学杂志,2011,40(8):553-557.
[17]《胃癌HER检测指南》专家组.胃癌HER2检测指南(2016版)[J].中华病理学杂志,2016,45(8):528-532.
[18]Kurokawa Y,Sugimoto N,Miwa H,et al.PhaseⅡstudy of trastuzumab in combination with S-1 plus cisplatin in HER2-positive gastric cancer(HERBIS-1)[J].British Journal of Cancer,2014,110(5):1163-1168.
[19]Nishikawa K,Takahashi T,Takaishi H,et al.PhaseⅡstudy of the effectiveness and safety of trastuzumab and paclitaxel for taxane-and trastuzumab-naive patients with HER2-positive, previously treated, advanced, or recurrent gastric cancer(JFMC45-1102)[J].International Journal of Cancer,2016,140(1):188-196.
[20]Yoshioka T,Shien K,Namba K,et al.Antitumor activity of pan-HER inhibitors in HER2-positive gastric cancer[J].Cancer Science,2018,109(4):1166-1176.
[21]Dai GH,Shi Y,Chen L,et al.Trastuzumab combined with docetaxel-based regimens in previously treated metastatic gastric cancer patients with HER2 over-expression[J].Hepatogastroenterology,2012,59(120):2439-2444.
[22]Mitsui Y,Sato Y,Miyamoto H,et al.Trastuzumab in combination with docetaxel/cisplatin/S-1(DCS)for patients with HER2-positive metastatic gastric cancer:feasibility and preliminary efficacy[J].Cancer Chemotherapy&Pharmacology,2015,76(2):375-382.
[23]Al-Batran SE,Hozaeel W,Jager E.Combination of trastuzumab and triple FLOT chemotherapy(5-fluorouracil/leucovorin, oxaliplatin, and docetaxel)in patients with HER2-positive metastatic gastric cancer:report of 3 cases[J].Onkologie,2012,35(9):505-508.
[24]Bang YJ,Van Cutsem E,Feyereislova A,et al.Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer(ToGA):a phase 3, open-label, randomised controlled trial[J].Lancet,2010,376(9742):687-697.
[25]Liang JW,Zhang JJ,Zhang T,et al.Clinicopathological and prognostic significance of HER2 overexpression in gastric cancer:a meta-analysis of the literature[J].Tumor Biology,2014,35(5):4849-4858.
[26]Grabsch H,Sivakumar S,Gray S,et al.HER2 expression in gastric cancer:Rare, heterogeneous and of no prognostic valueconclusions from 924 cases of two independent series[J].Cell Oncol,2010,32(1-2):57-65.
[27]Kang YK,Rha SY,Tassone P,et al.A phaseⅡa dose-finding and safety study of first-line pertuzumab in combination with trastuzumab, capecitabine and cisplatin in patients with HER2-positive advanced gastric cancer[J].British Journal of Cancer,2014,111(4):660-666.
[28]Satoh T,Xu RH,Chung HC,et al.Lapatinib plus paclitaxel versus paclitaxel alone in the second-line treatment of HER2-amplified advanced gastric cancer in Asian populations:TyTAN--a randomized, phaseⅢstudy[J].Journal of Clinical Oncology,2016,32(19):2039-2049.